Featured image: 90% of Alzheimer's patients would have been excluded from aducanumab trials

Author: Erica Davies

Erica is our staff writer and oversees the overall content on Drugwatcher.

Leave a Reply

Your email address will not be published. Required fields are marked *

Tell us your story

Please enter information


    We care about your privacy. By clicking the button you accept our disclaimer and privacy policy